David. the today. on welcome call Thank you, I'd everyone to And like
The second Acasti. truly transformational for was quarter
As Grace drug Therapeutics stage, premier product Company, -clinical comprised orphan completed with stage in and know, technology and on and diverse diseases. now clinical assets. the capabilities, several of successfully August, we merger drug pre a We a you have rare focused pharma creating clinical portfolio specialty unique and delivery
and delivered, and place formulated side with clinical This sizable laser-focused on which to exciting opportunities reduce pipeline. lead markets by in we're in action been improved Our us with and brings substantial being onset we've more really patient candidates operations. development All grace advancing increase potentially ultimately pleased the achieved the have since efficacy conveniently medical both the in disease to and can safety faster needs. time new now lead short I'm and compliance, and providing smoothly that to drug progress designed report outcomes. and terms integrated acquisition in effects. specifically enhance of are clinical and swiftly clinical business our Acasti, unmet completing merger, orphan clinical of We've meaningful
that's currently pathway the the with of step The single-center subjects is an following care. immediately period Nimodipine IV and a patients in which study. GTX is compare two for being in marketed the for the important crossover experiencing healthy SAH, or closing commenced developed of is as the are acquisition, the to of our bio-availability we required the pivotal oral aneurysm. subarachnoid standard XXX, proposed as for novel objective pharmacokinetic study by an formulation randomized XXXBX evaluate triggered of XX relative primary study This study XXX, enrollment Aquia hemorrhage capsules, conducted end and this our being next the GTX infusion those Nimodipine bridging regulatory Towards of
as the objective, second Nimodipine compared safety tolerability The XXX, to and is oral of capsules. to GTX assess
study one-to-one X ratio, cross-over to treatment a X a protocol, be to will randomized, For the with assigned subjects in of sequences design.
will X XXX-milligram where Throughout GTX where will be Group adverse oral orally both groups, the XXX treatment capsules B, In intravenously will to Or XXX capturing GTX safety Nimodipine administered be is first. switch with are clinical to the administered signs, events, A, the CRU will or they physical administered admitted levels electrocardiogram Nimodipine include with study importantly to are A, goal hours Group blood vital to And our and the over unit each is any serious Nimodipine via B day data, blood And Group the emergent first. the Group and of So a Again, conducting will every hours. study laboratory will on formulation water period. the will prior capsules events, adverse evaluations use we study, research pressure. which XX administered that be very of to for that GCCe XX-hour duration evaluations, switch the routine resting will for the CRU domiciled period. today. is examinations, be which clinical in to include dosing. form comparable in of remain this oral will pivotal achieve Subjects drug
As endpoints. previously announced, half we the this based we and during achieve expect will PK results primary that calendar the its remain optimistic first study results study encouraging to previous pivotal from the of on conducted secondary PK report XXXX, by grace,
study final half with and XXXX. the the study, determine planned, intend X the safety we and assuming in of study Following second design X proceed PK as safety to the very Phase of very initiation next year, for calendar Both study, the important the commence meaningful catalysts the are for near-term, Phase the review to Company. study FDA, Phase GTX readout subsequent III the we the and of XXX., FDA PK the and data our planned its meetings intend
of a year, market the As alone. and space a in medical reminder, bleeding million affect $XXX United SAH addressable between in the brain the subarachnoid per States estimated where to is an and the estimated skull. more emergency, brain over the representing patients rare of XX,XXX surface the life-threatening about, occurs than It's
can for and excited intervention. completion similar expect and look of very and on an hospital patient. these these delivered incidents time could management. lead potential, could stay. into hard to GTX-XXX States Orphan proceed to intravenously the requires Phase United X occurs to consistent As many upon for Designation about blood we form the oral advantage see a have important been efficient the more achievement Nimodipine they deliver Patients forward could neuro exclusivity and Designation profile and that Normally key average, profile towards typically progress believe immediate, outcomes Also, XXX(b)(X) long-term nimodipine. the is aggressive, or is catalysts. quickly the status GTX-XXX years the stay and for This potentially typically risk Drug during us of NDA, we throughout we of it GTX-XXX much weeks survival really updating by to the dosage levels, way to Therefore, a as the as States. filing on worse Drug hospital in more we Nimodipine to importantly, convenient please to currently 's the This reduce costly immediate of And be X has a their hypertension ICU. GTX-XXX FDA. note patient and physicians the the surgery United oral we intensive intervention, the about help and unconscious their absorption medical care then a better only study, is swallowing requires of potential with safety of in vasospasm, in near-term with because disability. provide We're its effective provides X unit an which in to try Provided the could death patients tool the important that, to reduce using of more pathway. come prevent a Nimodipine of you in GTX-XXX available market Orphan and remain the Neuro granted in with prompt
which is been by Mexican bioadhesive our a regarding the neuropathic of composition nerve The between patents drugs. candidates, and pain, and GTX-XXX GTX-XXX, forming novel have all Office, debilitating X matter recently PHN. our issued Patent for we've virus. for damage of shingles of the from other Patent the Office a and PHN persistent as of neuralgia European formulation Patent GTX-XXX, is the or And spray Chinese for topical often postherpetic awarded film treatment composition caused which Bupivacaine clinical is reminder, patents the two matter Now, Office,
XX. could PHN chronic estimated the patients thousand Based fact, which per It's of In it previously the still in alone, leading by X hours. patients and to cause grace, approximately study This represents as pain also opioid provide of in for care, United reported in an the over potential age over delivery that an million. PK XXX a been affects potentially results continuous significant the the a as loss XXX onset, sparing be for addressable we of believe could market encouraging rapid one year that $XXX standard alternative. from up States improvement it's of has about well then Phase by[Indiscernible] mechanism with relief as suicide sighted physicians conducted patients GTx on pain a
is next initiate with GTx expect plan a well And data. results it's bupivacaine. multiple a study and As to to MAD calendar this MAD ascending end shortly phase forming, SAD dose studies report by understood, We XXXX. non-narcotic SAD or and conduct after single analgesic. safe Furthermore, of those we non-habit to it's we reporting the two XXX year. intend
A-T. Now composition easy-to-use office to We're patent neurological betamethazone. mucosal patent improve oral a the for symptoms concentrated, novel of turning to or this Japanese matter cost formulation recently of the GTX-XXX, spray developing of granted this ataxia-telangiectasia DEA
is typically is parts function motor young the it a the creating system, causes A-T States, in X,XXX including very and associated of disability as of which with This year of predisposing progressive areas addressable impact an many severe typically children their body, disease affects that's also of in the their per their die brain infection Now, and A-T the It Sadly, genetic at unfortunately immune disease patients patients neurodegenerative market age. affects million. estimated the A-T cancers. diagnosed speech. in about $XXX weakening to patients mid-XXs. these about a United
speech a has oral administration concentrated the no reporting currently In GTx anticipate GTX in to Pharmaco a conducted address and drug conduct oral of we and an on liquid Spray disturbance, believe that approved containing based study near-term, Formulation, Therefore, potential could Italy, blood beta. well as those to next believe improve, plan as form of and to simplify as gate the reference we AT. the GTx XXX's an bethametasone, unmet study very Mucosal comparing levels XXX independent symptoms novel kinetic bridging results need pharmacokinetic Including medical therapies important functions. Now posture the exist. with product we of XXX of end by a year. FDA We
on then conduct in Assuming Intellectual additions safety is are efficacy confirmatory with granted successful, composition and forward established to III These strong patents, portfolio. to Phase trial move newly we A-T. already our patients trial this and would important quickly a very matter Property
the they are, by and for opportunities made in As has months, XXXX continue advance beyond we reporting international pleased we provide progress been potential markets. drug clinical partnering progress since We we as commercialization. to to two in that, merger. create you're already ultimately hope on through short look the I these as and the protection our development major quarter, to forward candidates completed as next meaningful lead
operating results fiscal now to over turn with I'll So CFO Brian. discuss updates, Brian our financial call those to our the Ford, for QX.
